{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:47:16Z","timestamp":1788288436994,"version":"build-2803163510"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>We reviewed the available information on the use of immune checkpoint inhibitors (ICIs) in populations with special conditions, namely, patients with HIV, tuberculosis, or underlying autoimmune disease. Available data show that treatment with ICIs is safe in patients with HIV; it is advisable, however, that these patients receive adequate antiretroviral therapy and have an undetectable viral load before ICIs are initiated. Tuberculosis reactivation has been reported with the use of ICIs, possibly due to immune dysregulation. Tuberculosis has also been associated with the use of immunosuppressors to treat immune-related adverse events (irAEs). Active tuberculosis must be ruled out in patients with symptoms or signs, and selected patients may benefit from screening for latent tuberculosis infection, although more data are required. Limited data exist regarding the safety of ICIs in patients with cancer and autoimmune disease. Data from observational studies suggest that up to 29% of patients with a preexisting autoimmune disease treated with an ICI present with an autoimmune disease flare, and 30% present with a <jats:italic>de novo<\/jats:italic> irAE of any type. The frequency of flares appears to differ according to the type of ICI received, with higher rates associated with PD-1\/PD-L1 inhibitors. The most common autoimmune diseases for which patients reported flares with ICI therapy are rheumatoid arthritis, other inflammatory arthritis, and psoriasis. Most studies have reported flares or <jats:italic>de novo<\/jats:italic> irAEs associated with ICIs that were mild to moderate, with low rates of discontinuation and no deaths due to flares. Therefore, the use of ICIs in these patients is possible, but careful monitoring is required.<\/jats:p>","DOI":"10.3389\/fmed.2022.875910","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T05:17:55Z","timestamp":1657862275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Multidisciplinary approach to treatment with immune checkpoint inhibitors in patients with HIV, tuberculosis, or underlying autoimmune diseases"],"prefix":"10.3389","volume":"9","author":[{"given":"Juan","family":"Aguilar-Company","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Lopez-Olivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Ruiz-Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40364-021-00314-8","article-title":"Risk factors for immune-related adverse events: what have we learned and what lies ahead?","volume":"9","author":"Liu","year":"2021","journal-title":"Biomark Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2017","journal-title":"Lancet HIV."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0129550","DOI":"10.1371\/journal.pone.0129550","article-title":"Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000","volume":"10","author":"Vandenhende","year":"2015","journal-title":"PLoS ONE."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1001\/jamainternmed.2017.4349","article-title":"Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States","volume":"177","author":"Reddy","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1200\/JCO.2007.14.5532","article-title":"Including persons with HIV infection in cancer clinical trials","volume":"26","author":"Persad","year":"2008","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"102836","DOI":"10.1016\/j.critrevonc.2019.102836","article-title":"Treating cancer with immunotherapy in HIV-positive patients: a challenging reality","volume":"145","author":"Guaitoli","year":"2020","journal-title":"Crit Rev Oncol Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1097\/QAD.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS."},{"key":"B11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/QAI.0b013e3181fbab9f","article-title":"Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment","volume":"56","author":"Grabmeier-Pfistershammer","year":"2011","journal-title":"JAIDS J Acquir Immune Defic Syndr."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the Anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"215","author":"Gay","year":"2017","journal-title":"J Infect Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer\u2014a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12094-018-1981-6","article-title":"Cancer immunotherapy of patients with HIV infection","volume":"21","author":"Gonzalez-Cao","year":"2019","journal-title":"Clin Transl Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS."},{"key":"B17","doi-asserted-by":"publisher","first-page":"102011","DOI":"10.1016\/j.ctrv.2020.102011","article-title":"The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B\/C, HIV): a review of the available evidence","volume":"86","author":"Tapia Rico","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3390\/cells10092227","article-title":"Immune checkpoint inhibitors in people living with HIV\/AIDS: facts and controversies","volume":"10","author":"Castelli","year":"2021","journal-title":"Cells."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e001664","DOI":"10.1136\/jitc-2020-001664","article-title":"Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)","volume":"9","author":"Gonzalez-Cao","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"204993612198954","DOI":"10.1177\/2049936121989548","article-title":"Risk of infection associated with targeted therapies for solid organ and hematological malignancies","volume":"8","author":"Ruiz-Camps","year":"2021","journal-title":"Ther Adv Infect Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)","volume":"24","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/cid\/ciw838","article-title":"Risk of active tuberculosis in patients with cancer: a systematic review and metaanalysis","volume":"64","author":"Cheng","year":"2017","journal-title":"Clin Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00157-2017","article-title":"Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis","author":"Dobler","year":"2017","journal-title":"Eur Respir J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"13402","DOI":"10.1073\/pnas.1007394107","article-title":"Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis","volume":"107","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.4049\/jimmunol.1003304","article-title":"CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition","volume":"186","author":"Barber","year":"2011","journal-title":"J Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1005667","DOI":"10.1371\/journal.ppat.1005667","article-title":"CD4 T Cell-derived IFN-\u03b3 plays a minimal role in control of pulmonary mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease","volume":"12","author":"Sakai","year":"2016","journal-title":"PLoS Pathog."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-36403-2","article-title":"PD-1\/PD-L1 pathway modulates macrophage susceptibility to mycobacterium tuberculosis specific CD8+ T cell induced death","volume":"9","author":"Suarez","year":"2019","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1086\/654932","article-title":"Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis","volume":"202","author":"Alvarez","year":"2010","journal-title":"J Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Care Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents)","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2020.03.015","article-title":"Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature","volume":"132","author":"Zaemes","year":"2020","journal-title":"Eur J Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0717-7","article-title":"Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations","volume":"7","author":"Anastasopoulou","year":"2019","journal-title":"J ImmunoTherapy Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention Clinical Practice guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: an old disease in a new context","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002960","article-title":"Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study","volume":"9","author":"Bae","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.12691\/ijcd-3-4-8","article-title":"The world incidence and prevalence of autoimmune diseases is increasing","volume":"3","author":"Lerner","year":"2015","journal-title":"Int J Celiac Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00002281-200303000-00002","article-title":"Environmental epidemiology and risk factors for autoimmune disease","volume":"15","author":"Dooley","year":"2003","journal-title":"Curr Opin Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","article-title":"Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases","volume":"33","author":"Cooper","year":"2009","journal-title":"J Autoimmun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.21873\/anticanres","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2147\/CLEP.S47150","article-title":"The impact of comorbidity on cancer survival: a review","volume":"5","author":"S\u00f8gaard","year":"2013","journal-title":"Clin Epidemiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0256536","DOI":"10.1371\/journal.pone.0256536","article-title":"The impact of chronic comorbidities at the time of breast cancer diagnosis on quality of life, and emotional health following treatment in Canada","volume":"16","author":"Arneja","year":"2021","journal-title":"PLoS ONE"},{"key":"B45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3322\/caac.21342","article-title":"The impact of comorbidity on cancer and its treatment","volume":"66","author":"Sarfati","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"B46","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer."},{"key":"B48","unstructured":"Safety of immune checkpoint inhibitors for the treatment ofmelanoma, bronchopulmonary and urologic neoplasms in patients with preexisting autoimmune disease-ACR meeting abstracts\n            TisonA\n            QuereG\n            MiseryL\n            LesimpleT\n            MarcqM\n            MartinezS\n          Arthritis Rheumatol2017"},{"key":"B49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/annonc\/mdw056","article-title":"The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma","volume":"27","author":"Lee","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1200\/JCO.2017.35.15_suppl.3018","article-title":"FDA analysis of patients with baseline autoimmune diseases treated with PD-1\/PD-L1 immunotherapy agents","volume":"35","author":"Weinstock","year":"2017","journal-title":"J Clin Oncol."},{"key":"B52","article-title":"Rheumatological immune related adverse events in malignancy patients treated with anti-programmed cell death (PD) 1 antibodies, vol","author":"Mitchell","year":"2017"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","author":"Menzies","year":"2017","journal-title":"Ann Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"Kahler","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the mayo clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B58","unstructured":"Systematic review and meta-analysis of observational studies reporting on the use of checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease\n            Lopez-OlivoM\n            Abdel-WahabN\n            Su\u00e1rez-AlmazorMA\n          Arthritis Rheumatol.2019"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist."},{"key":"B60","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Cancer Netw."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.875910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T05:18:00Z","timestamp":1657862280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.875910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":61,"alternative-id":["10.3389\/fmed.2022.875910"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.875910","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"article-number":"875910"}}